Stereotactic Body Radiation With Nelfinavir for Oligometastases
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Patients with metastatic lesions of the lung, liver, or bone will be candidates for
treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion
site) of SBRT will be administered. Prior to SBRT, patients will initiate Nelfinavir oral
therapy twice daily for 7 days. Once SBRT is completed, the patient will repeat the same
Nelfinavir therapy for an additional 7 days for a total of 14 days of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins